FDA considers issuing more final guidances without comment period
Regulatory NewsJoanne S. Eglovitch
Audit/inspectionBiologics/ biosimilars/ vaccinesChemistry, Manufacturing and Controls (CMC)Clinical TrialsComplianceMedical DevicesPharmaceuticalsPharmacovigilancePreclinical studyRegulatory Intelligence/PolicyUnited States